BioMarin Pharmaceuticals
BMRN
561 hedge funds and large institutions have $11.1B invested in BioMarin Pharmaceuticals in 2026 Q2 according to their latest regulatory filings, with 87 funds opening new positions, 200 increasing their positions, 196 reducing their positions, and 77 closing their positions.
187% more call options, than puts
Call options by funds: $114M | Put options by funds: $39.7M
27% more funds holding in top 10
Funds holding in top 10: 11 → 14 (+3)
13% more first-time investments, than exits
New positions opened: 87 | Existing positions closed: 77
7% more capital invested
Capital invested by funds: $10.4B → $11.1B (+$707M)
4.69% more ownership
Funds ownership: 95.5% → 100.19% (+4.7%)
2% more repeat investments, than reductions
Existing positions increased: 200 | Existing positions reduced: 196
1% more funds holding
Funds holding: 557 → 561 (+4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VPC
Vestal Point Capital
New York
|
+$134M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$118M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$68.8M |
| 4 |
AIM
ARGA Investment Management
Stamford,
Connecticut
|
+$56.9M |
| 5 |
Goldman Sachs
New York
|
+$45M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$186M |
| 2 |
AQR Capital Management
Greenwich,
Connecticut
|
-$108M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$67.7M |
| 4 |
Millennium Management
New York
|
-$51.4M |
| 5 |
Pictet Asset Management
Carouge,
Switzerland
|
-$43.7M |
BMRN Hedge Fund Activity: Q2 2026 in Review
561 of the 8,279 institutional investors tracked by Wall St. Rank reported a position in BioMarin Pharmaceuticals (BMRN) for Q2 2026, worth a combined $11.1B — up 6.8% from $10.4B a quarter earlier.
Buyers outnumbered sellers: 87 funds opened new BMRN positions and 77 closed out — a net gain of 10 holders — while 200 added to existing stakes and 196 trimmed.
The largest buyer was Vestal Point Capital, adding an estimated $134M. The largest seller was Citadel Advisors, cutting an estimated $186M.
- 561 institutional investors held BioMarin Pharmaceuticals (BMRN) as of Q2 2026, up from 557 in Q1 2026.
- Funds reported $11.1B of BioMarin Pharmaceuticals stock for Q2 2026, up 6.8% quarter-over-quarter.
- 87 funds opened new BioMarin Pharmaceuticals positions in Q2 2026 and 77 closed out, a net change of +10 holders.
- The largest BioMarin Pharmaceuticals buyer in Q2 2026 was Vestal Point Capital, an estimated $134M added.
- The largest BioMarin Pharmaceuticals seller in Q2 2026 was Citadel Advisors, an estimated $186M sold.
Based on aggregated 13F filings for Q2 2026.